Top Markets
Coin of the day
Oragenics, Inc. Oragenics, Inc.

Oragenics, Inc.

OGEN
株式のランク #36713
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on... Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
株価
$0.5301
最終同期: 2026-08-14
時価総額
$2.39M
変化(1日)
0.00%
変化(1年)
-53.90%
US
取引 Oragenics, Inc. (OGEN)

カテゴリー

Oragenics, Inc.(OGEN)のP/S比率
2026 時点のP/S比率 TTM: 0
Oragenics, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Oragenics, Inc. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE